InvestorsHub Logo

cjarmstrong

07/31/17 2:18 AM

#2650 RE: AntonChigurh #2647

Inferior regarding quality or safety.

I've already explained why it could theoreticaly be a consideration.

I never suggested smoking/edibles were superior.

What study did you reference? No matter, I mentioned IV only because I said transmucosal and transdermal are the most effective methods of delivery, other than IV which would have a 100% bioavailability.

CB1 receptors develop a tolerance to THC fairly quickly, which could affect IOP reduction. It's simply a concern, this is why it's important to account for risk when valuing a drug. We've discussed this - you (I'm paraphrasing) suggested Elsohly et al will figure it out, I thought that was strange and then went to Europe for a few weeks.

I simply asked vinpat whether or not he performed a valuation. If he did I'd be interested in knowing which valuation method and variables he used.